NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects
Press releases
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 2 pm on Thursday 22 March 2018 at Medicon Village, Scheelevägen 2 ...
NeuroVive decides on a Rights issue for continued drug development
Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "th ...
NeuroVive reports breakthrough in mitochondrial myopathy project
Lund, Sweden, 29 January 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondria ...
NeuroVive to Present at the 10th Annual Biotech Showcase Conference
Lund, Sweden, 3 January 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced that the company is scheduled to present the 10th Annual Biotech Showcase Conference, ...